Indications
Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
Composition
- Active substance
- Fostamatinib disodium
- International name (INN)
- fostamatinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tavlesse
- Active substance
- Fostamatinib disodium
- ATC code
- B02BX
- Therapeutic area
- Thrombocytopenia
- Marketing authorisation holder
- Instituto Grifols S.A.
- Status
- Authorised